Filter results
![](https://www.rovi.es/sites/default/files/img_7470.jpg)
11/07/2024
The Community of Madrid has declared this project to be strategic: it will create 200 new direct jobs for 2027 and raise the plant’s production capacity to 500 million injectables
![](https://www.rovi.es/sites/default/files/escuzar_0.jpg)
20/06/2024
ROVI reinforces its heparin production capacity
![](https://www.rovi.es/sites/default/files/_b0a0749_propuesta_q1_2024_2.jpg)
08/05/2024
ROVI closes the quarter with operating revenue of 151.2 million euros
![](https://www.rovi.es/sites/default/files/logo_rovi_600x600px_transparente.png)
25/04/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company
![](https://www.rovi.es/sites/default/files/_b0a1296.jpg)
02/04/2024
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults
![](https://www.rovi.es/sites/default/files/_b0a3821.jpg)
12/03/2024
This public-private collaboration instrument falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE) and will have an initial investment of over 74 million euros
![](https://www.rovi.es/sites/default/files/_boa2325.jpg_baja_calidad.png)
27/02/2024
ROVI achieved operating revenue growth of 1% in the first post-pandemic year